Maxcyte (MaxCyte Inc (AIM:MXCT)) - Doug Doerfler, CEO Presenting at the Proactive One2One Virtual Forum
MaxCyte is a world-leading provider of cell-engineering platform technologies that drives the next‐generation of cell and gene-editing therapies. The company's technology, which is designed to make a meaningful difference for patients, is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted for more than 140 cell therapy programs, with more than 100 licensed for clinical use, and the company has now entered into 12 clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US.